Agios Pharmaceuticals, Inc. Form 4 Filings

AGIOS PHARMACEUTICALS, INC. director Jay T. Backstrom reported equity compensation activity. On July 8, 2026, he acquired 1,447 shares of common stock at no cost, in connection with the exercise/vesting of 1,447 restricted stock units (RSUs). Following these transactions, he directly holds 1,447 common shares and 2,894 RSUs. The RSUs were originally granted on July 8, 2025 and are scheduled to vest in three equal annual installments beginning July 8, 2026.

Agios Pharmaceuticals Chief Medical Officer Sarah Gheuens reported routine equity compensation activity and related tax sales. On July 1, 2026, 8,375 restricted stock units converted into an equal number of common shares as part of a scheduled vesting from a July 1, 2023 grant.

To cover tax withholding from this vesting, 4,007 common shares were sold at $37.56 per share under durable automatic sale instructions designed to qualify for the Rule 10b5-1(c) affirmative defense. After these transactions, Gheuens directly holds 84,645 shares of Agios common stock.

AGIOS PHARMACEUTICALS director Rahul D. Ballal reported equity compensation transactions. He exercised 2,816 restricted stock units into common stock and, after these transactions, directly holds 15,230 common shares.

On the same date, he received 14,950 stock options at an exercise price of $34.16 per share, expiring on June 18, 2036, and 2,927 new restricted stock units. Footnotes state the exercised RSUs were granted on June 18, 2025 and vested on June 18, 2026, while the new RSUs and options were granted on June 18, 2026 and will vest in full on June 18, 2027.

AGIOS PHARMACEUTICALS director Jeffrey D. Capello reported equity awards and vesting activity. On June 18, 2026, 2,816 restricted stock units converted into the same number of common shares, increasing his direct holdings to 10,865 shares.

He also received new grants of 14,950 stock options with an exercise price of $34.16 per share, expiring on June 18, 2036, and 2,927 restricted stock units. According to the footnotes, options and RSUs granted on June 18, 2026 vest in full on June 18, 2027, with vested shares delivered within three business days. Earlier RSUs granted June 18, 2025 vest in full on June 18, 2026. These are compensation-related grants and exercises, not open-market purchases or sales.

AGIOS PHARMACEUTICALS, INC. director Kaye I. Foster-Cheek reported routine equity compensation and an option-related share delivery. On June 18, 2026, she exercised restricted stock units covering 2,816 shares of common stock, increasing her direct holdings to 10,284 shares. She also received a grant of 14,950 stock options with a $34.16 exercise price, expiring on June 18, 2036, and a separate award of 2,927 restricted stock units that will vest in full on June 18, 2027. In addition, 2,200 shares are held indirectly through the Foster Family Revocable Trust. These movements reflect compensation and conversions rather than open-market buying or selling.

AGIOS PHARMACEUTICALS director Jacqualyn A. Fouse reported equity compensation and a routine vesting event. On June 18, 2026, 2,816 restricted stock units vested and were converted into 2,816 shares of common stock, bringing her direct common stock holdings to 154,156 shares.

On the same date, she received new awards of 14,950 stock options with a strike price of $34.16 per share, expiring on June 18, 2036, and 2,927 new restricted stock units. These 2026 option and RSU grants are scheduled to vest in full on June 18, 2027. The filing shows only acquisitions, with no reported share sales.

AGIOS PHARMACEUTICALS director Maykin Ho reported compensation-related equity transactions. She exercised restricted stock units into 2,816 shares of common stock, bringing her direct holdings to 19,848 shares. She also received 14,950 stock options and 2,927 new restricted stock units, which vest in future years.

AGIOS PHARMACEUTICALS, INC. director Catherine Owen Adams reported equity compensation activity involving stock options, restricted stock units (RSUs), and common shares. She exercised RSUs to receive 2,816 shares of common stock, bringing her direct common stock holdings to 10,865 shares.

On the same date she was granted 14,950 stock options with a $34.16 exercise price, vesting fully on June 18, 2027, and 2,927 RSUs that also vest in full on June 18, 2027. Footnotes state earlier RSUs granted June 18, 2025 vested June 18, 2026, with shares delivered within three business days.

AGIOS PHARMACEUTICALS, INC. director David Scadden increased his equity-based holdings through option and RSU activity. On June 18, 2026, he acquired 2,816 shares of common stock via the exercise of previously granted restricted stock units, bringing his direct common stock ownership to 20,419 shares.

He also received new equity awards: 14,950 stock options with a $34.16 exercise price, vesting in full on June 18, 2027, and 2,927 new restricted stock units that also vest in full on June 18, 2027. Earlier RSUs granted on June 18, 2025 will vest in full on June 18, 2026, with shares delivered within three business days after vesting.

AGIOS PHARMACEUTICALS director Cynthia Smith reported equity compensation activity and an option exercise. On June 18, 2026, she exercised restricted stock units covering 2,816 shares of common stock, bringing her direct common stock holdings to 15,230 shares after the transaction.

She also received 14,950 stock options with an exercise price of $34.16 per share that vest in full on June 18, 2027, and 2,927 new restricted stock units that also vest on June 18, 2027. Earlier restricted stock units granted on June 18, 2025 vested in full on June 18, 2026, and the vested shares will be delivered within three business days after vesting.

AGIOS PHARMACEUTICALS, INC. reported that Chief Strategy and Operations officer Krishnan Viswanadhan acquired equity-based compensation on June 18, 2026. He received 3,000 restricted stock units, each representing a contingent right to one share of common stock, and a further 3,000 performance share units tied to clinical and research milestones. The performance share units were originally granted on March 5, 2025, and the compensation & people committee determined that the performance criteria for a specified research milestone were met as of June 18, 2026. Shares related to that milestone are scheduled to vest on December 31, 2027, subject to his continued service.

AGIOS PHARMACEUTICALS, INC. Chief Executive Officer Brian Goff reported equity compensation activity involving 39,000 shares. He received a grant of 39,000 restricted stock units, each representing a contingent right to receive one share of common stock. In addition, 39,000 performance share units tied to clinical and research milestones were exercised into underlying common stock. The performance criteria for a specified research milestone were determined to be met as of June 18, 2026, and the related shares are scheduled to vest on December 31, 2027, subject to his continued service.

AGIOS PHARMACEUTICALS, INC. Chief Legal Officer James William Burns reported routine equity compensation changes. He received a grant of 3,000 restricted stock units, each representing a right to one share of common stock. He also exercised 3,000 performance share units into common stock at no exercise price.

The performance share units were originally granted on March 1, 2025 and vest based on three specified clinical and research milestones. The compensation & people committee determined one research milestone was met as of June 18, 2026, and the related shares are scheduled to vest on December 31, 2027, subject to his continued service.

AGIOS PHARMACEUTICALS Chief Medical Officer Sarah Gheuens reported equity compensation activity involving restricted and performance share units. On June 18, 2026, she received a grant of 3,000 restricted stock units, each representing a contingent right to one share of common stock. The same day, she also acquired 3,000 shares of common stock through the exercise or conversion of 3,000 performance share units, with each unit likewise tied to one common share. These performance share units were originally granted on March 1, 2025 and vest based on three specified clinical and research milestones set by the board and its compensation and people committee. The performance criteria for one research milestone was determined to be met as of June 18, 2026, and the related shares are scheduled to vest on December 31, 2027, subject to Dr. Gheuens’s continued service. Following these transactions, she holds 3,000 restricted stock units and 9,000 performance share units, and the filing shows only acquisitions with no sales or tax-withholding dispositions.

Jones Cecilia reported acquisition or exercise transactions in this Form 4 filing.

AGIOS PHARMACEUTICALS, INC. Chief Financial Officer Cecilia Jones reported equity compensation activity involving restricted stock units and performance share units. She received a grant of 3,000 restricted stock units, each representing a contingent right to one share of common stock. A separate award of 3,000 performance share units tied to a specified research milestone had its performance criteria determined to be met as of June 18, 2026. The underlying shares for this milestone are scheduled to vest on December 31, 2027, subject to her continued service.

AGIOS PHARMACEUTICALS, INC. Chief Commercial Officer Tsveta Milanova reported equity-based compensation changes involving restricted and performance share units tied to common stock. She received 3,000 restricted stock units, each representing a contingent right to one share of common stock, bringing her holdings in that award type to 3,000 units.

She also acquired 3,000 shares through the exercise of performance share units, increasing her total directly held common stock from these derivative transactions to 9,000 shares. The performance stock units were originally granted on March 1, 2025 and vest based on three specified clinical and research milestones. The performance criteria for a specified research milestone were determined to be met as of June 18, 2026, and the related shares are scheduled to vest on December 31, 2027, subject to her continued service.

AGIOS PHARMACEUTICALS, INC. director Jay T. Backstrom received new equity awards as part of his compensation. He was granted stock options for 14,950 shares of common stock at an exercise price of $34.16 per share, vesting in full on June 18, 2027 and expiring on June 18, 2036.

He also received 2,927 restricted stock units, each representing a contingent right to one share of common stock. These RSUs vest in full on June 18, 2027, with shares to be delivered within three business days after vesting. These are routine awards, not open-market purchases or sales.

AGIOS PHARMACEUTICALS director Catherine Owen Adams exercised restricted stock units into common stock. She converted 1,976 restricted stock units into 1,976 shares of common stock at a stated price of $0.00 per share and did not sell any shares. Following the transaction, she directly holds 8,049 shares of common stock. The restricted stock units were granted on June 13, 2023 and vest in three equal annual installments beginning on June 13, 2024, with vested shares delivered within three business days after vesting.

AGIOS PHARMACEUTICALS, INC. director Jeffrey D. Capello reported the vesting and conversion of previously granted restricted stock units into common shares. On June 13, 2026, he exercised 1,976 restricted stock units into 1,976 shares of common stock at a stated price of $0.00 per share, reflecting a compensation-related equity award rather than an open-market purchase. These units were part of a grant made on June 13, 2023, scheduled to vest in three equal annual installments beginning June 13, 2024. After this transaction, Capello directly holds 8,049 shares of Agios common stock.

Agios Pharmaceuticals Chief Legal Officer James William Burns exercised 8,500 performance share units into 8,500 shares of common stock. The PSUs vested when a specified regulatory milestone was determined to be met on April 2, 2026. On the same date, 3,280 shares were sold at $34.71 per share to cover tax withholding obligations under durable automatic sale instructions consistent with Rule 10b5-1(c). Following these transactions, Burns directly holds 49,306 shares of Agios common stock.

AGIOS PHARMACEUTICALS, INC. Chief Medical Officer Sarah Gheuens exercised performance share units that converted into 8,500 shares of common stock on April 2, 2026 after a specified regulatory milestone was achieved.

Each performance share unit represented a contingent right to receive one share of common stock, and the grant was originally made on March 1, 2024. Following this vesting and exercise, Gheuens sold 2,940 shares of common stock at $34.71 per share to cover tax withholding obligations under durable automatic sale instructions consistent with Rule 10b5-1(c). After these transactions, she directly owns 80,277 common shares, which include 311 shares purchased through the company’s employee stock purchase plan.

Agios Pharmaceuticals' Chief Financial Officer Cecilia Jones exercised performance share units and sold shares primarily to cover taxes. She converted 8,500 performance share units into 8,500 shares of common stock after a specified regulatory milestone was determined to have been met on April 2, 2026. On the same date, 3,141 shares were sold at $34.71 per share to satisfy tax withholding obligations under durable automatic sale instructions included in her March 1, 2024 performance share unit agreement, which is structured to be consistent with the Rule 10b5-1(c) affirmative defense. After these transactions, she directly held 54,998 shares of common stock, including 311 shares acquired through the company’s employee stock purchase plan.

Agios Pharmaceuticals Chief Commercial Officer Tsveta Milanova reported a vesting and tax-related sale of shares. On April 2, 2026, 8,500 performance share units were exercised into 8,500 shares of common stock at $0.00 per share, reflecting the vesting of performance-based equity compensation tied to a specified regulatory milestone.

On the same date, 3,262 shares of common stock were sold at $34.71 per share to cover tax withholding obligations, executed under durable automatic sale instructions consistent with Rule 10b5-1(c). After these transactions, Milanova directly owned 46,829 shares of Agios common stock.

Agios Pharmaceuticals executive Krishnan Viswanadhan reported an exercise-and-sell transaction tied to performance share units (PSUs). On April 2, 2026, 8,100 PSUs converted into 8,100 shares of common stock at $0.00 per share when a specified regulatory milestone was achieved.

On the same date, 2,959 shares were sold at $34.71 per share to cover tax withholding obligations under durable automatic sale instructions consistent with Rule 10b5-1(c). After these transactions, he held 10,282 shares of Agios common stock directly.

Agios Pharmaceuticals Chief Executive Officer Brian Goff reported vesting and settlement of performance share units tied to regulatory milestones, resulting in the delivery of 39,028 shares of common stock. On the same date, 19,068 shares were sold at $34.71 per share to cover tax withholding obligations under durable automatic sale instructions consistent with Rule 10b5-1(c). Following these compensation-related transactions, he holds 184,508 common shares directly.

Agios Pharmaceuticals executive Krishnan Viswanadhan, Chief Corp Dev & Strategy, reported several equity transactions on March 5, 2026 tied to restricted stock units (RSUs). He exercised 8,100 RSUs, converting them into 8,100 shares of common stock at a price of $0.00 per share, reflecting the nature of RSUs as equity awards rather than open-market purchases. Following this, 2,959 common shares were sold at $27.80 per share to cover tax withholding obligations related to the RSU vesting, under durable automatic sale instructions consistent with Rule 10b5-1(c). After these transactions, he directly held 16,200 RSUs and 5,141 common shares. The RSUs were granted on March 5, 2025, with the underlying shares scheduled to vest in three equal annual installments beginning March 5, 2026.

AGIOS PHARMACEUTICALS, INC. reported that Principal Accounting Officer Theodore James Washburn Jr. completed an open-market sale of common stock. On March 3, 2026, he sold 5,272 shares at a price of $28.88 per share and held 868 shares of common stock afterward.

AGIOS PHARMACEUTICALS, INC. Chief Executive Officer Brian Goff reported multiple equity-related transactions in company stock. On March 1, 2026, he received 48,000 restricted stock units and 174,000 stock options, each RSU representing the right to receive one share of common stock, with both awards vesting over several years as described.

On March 2, 2026, previously granted restricted stock units vested and were converted into common shares through exercises of 8,500, 18,000, and 13,000 RSUs. In connection with these vestings, he sold a total of 18,055 shares of common stock at $28.96 per share to cover tax withholding obligations, under durable automatic sale instructions referenced as compliant with Rule 10b5-1(c). After these transactions, he directly held 164,548 shares of AGIOS common stock.

AGIOS PHARMACEUTICALS, INC. Chief Legal Officer James William Burns reported multiple equity transactions. On March 1, 2026, he received grants of 14,000 restricted stock units and 52,000 stock options, both vesting over several years beginning March 1, 2027. On March 2, 2026, he exercised previously granted restricted stock units into common shares and reported open-market sales totaling 5,218 common shares at $28.96 per share to cover tax withholding obligations related to performance share vesting. These sales were executed under durable automatic sale instructions consistent with Rule 10b5-1(c). Following these transactions, he directly held 44,086 common shares.

AGIOS PHARMACEUTICALS Chief Medical Officer Sarah Gheuens reported multiple equity transactions. On March 2, 2026, she exercised restricted stock units into common shares and sold a total of 4,055 common shares at $28.96 per share to cover tax withholding obligations under pre-set Rule 10b5-1 instructions. Following these transactions, she directly held 74,406 shares of common stock. On March 1, 2026, she also received equity compensation grants of 14,000 and 22,000 restricted stock units and 52,000 stock options, all vesting over multi-year schedules beginning in March 2027.

AGIOS PHARMACEUTICALS, INC. Chief Financial Officer Cecilia Jones reported a mix of equity awards, vesting and related share sales. On March 1, 2026, she received 14,000 restricted stock units and stock options for 52,000 shares, with RSUs vesting in three equal annual installments and the option vesting 25% on March 1, 2027 and the remaining 75% in 36 equal monthly installments.

On March 2, 2026, multiple restricted stock unit tranches were exercised into common stock, and a total of 5,035 common shares were sold at $28.96 per share. Footnotes state these sales were made to cover tax withholding obligations under durable automatic sale instructions consistent with Rule 10b5-1(c) and included in prior restricted stock unit agreements. After these transactions, she directly owned 49,328 common shares of Agios common stock.

AGIOS PHARMACEUTICALS, INC. Chief Commercial Officer Tsveta Milanova reported a mix of equity grants, vesting, and tax-related share sales. On March 1, 2026, she received 14,000 restricted stock units and 52,000 stock options, with both awards vesting over multiple years starting March 1, 2027.

On March 2, 2026, previously granted restricted stock units vested, converting into 5,666 and 4,000 shares of common stock at no cost through derivative exercises. To cover tax withholding from these vestings, she sold 2,868 shares of common stock in open-market transactions at $28.96 per share under durable automatic Rule 10b5-1 instructions. After these trades, she continued to hold tens of thousands of shares directly.

AGIOS PHARMACEUTICALS, INC. principal accounting officer Theodore James Washburn Jr. reported multiple equity transactions linked to restricted stock units. On March 1, 2026, he received a grant of 8,452 restricted stock units, each representing a contingent right to one share of common stock, vesting in three equal annual installments beginning March 1, 2027.

On March 2, 2026, restricted stock units granted in 2023, 2024 and 2025 vested, with 2,350, 2,450 and 2,695 units respectively converting into common stock at no cost. To cover tax withholding obligations from these vestings, he sold a total of 2,223 shares of common stock in open-market transactions at $28.96 per share pursuant to durable automatic sale instructions under Rule 10b5‑1. Following these transactions, he held 6,140 common shares directly, including 75 shares acquired through the company’s employee stock purchase plan.

AGIOS PHARMACEUTICALS, INC. executive Krishnan Viswanadhan, Chief Corporate Development & Strategy, reported equity compensation grants rather than market purchases or sales. He received 14,000 restricted stock units, each representing a right to one share of common stock.

The restricted stock units were granted on March 1, 2026 and will vest in three equal annual installments beginning March 1, 2027. He was also granted stock options covering 52,000 shares at a per-share exercise price of $0.00, vesting 25% on March 1, 2027 and the remaining 75% in 36 equal monthly installments thereafter.

Agios Pharmaceuticals Chief Commercial Officer Tsveta Milanova reported the vesting and related sale of company stock. On January 5, 2026, 8,475 restricted stock units were converted into an equal number of Agios common shares at an exercise price of $0. On the same day, 2,872 of those shares were sold at $27.02 per share to cover tax withholding obligations, under durable automatic sale instructions intended to satisfy Rule 10b5-1(c). After these transactions, Milanova directly held 34,793 shares of Agios common stock.

Agios Pharmaceuticals (AGIO) reported an insider transaction by its Chief Medical Officer. On 11/11/2025, the officer exercised stock options for 2,454 shares at $25.01 per share and sold 2,454 common shares at a weighted average price of $43.78 under a Rule 10b5-1 trading plan.

Following these transactions, the officer beneficially owns 61,727 common shares directly. The option exercised was part of a grant originally awarded on March 1, 2023, with vesting beginning on March 1, 2024 and continuing monthly thereafter.

Agios Pharmaceuticals (AGIO) reported an insider transaction by its Chief Medical Officer, Sarah Gheuens. On 10/30/2025, she exercised 200 stock options at $25.01 per share and sold 200 shares at $43.81 pursuant to a Rule 10b5-1 trading plan. Following these trades, she held 61,727 shares of common stock directly.

The derivative table shows 28,584 stock options beneficially owned after the transaction, with an exercise price of $25.01 and an expiration date of 03/01/2033. The option was originally granted on 03/01/2023 for 44,000 shares, vesting 25% on 03/01/2024 with the remainder vesting in 36 equal monthly installments thereafter.

Agios Pharmaceuticals (AGIO) reported an insider transaction by its Chief Medical Officer on 10/27/2025. The officer exercised 3,302 stock options at $25.01 per share and sold 3,302 common shares at a $43.92 weighted average price pursuant to a Rule 10b5-1 trading plan.

Following these transactions, the officer directly beneficially owned 61,727 common shares. The filing also lists 28,784 stock options remaining beneficially owned. The sale price ranged from $43.77 to $44.13, and the reporting person undertakes to provide the detailed breakdown upon request. Footnotes note that ownership includes 456 shares acquired through the employee stock purchase plan and that the exercised option was part of a grant originally awarded on March 1, 2023.

Insider transactions by Director David Scadden show option exercise and a share sale under a 10b5-1 plan. On 10/08/2025 Mr. Scadden exercised 200 stock options with an $18.09 exercise price, creating 200 new shares.

He simultaneously sold 200 shares at $41, leaving him with 17,603 shares of common stock directly and 27,107 shares underlying options and other derivative holdings in total. The exercise option was originally granted on 06/21/2022 and vests 100% one year from the grant date. The transactions were made pursuant to a Rule 10b5-1 trading plan.

David Scadden, a director of Agios Pharmaceuticals (AGIO), reported trading activity executed on 09/30/2025 under a Rule 10b5-1 trading plan. The filing shows a purchase of 200 common shares at $18.09 and a sale of 200 common shares at $40.00 on the same date. After those transactions Mr. Scadden reported beneficial ownership of 17,603 shares of common stock and, including derivative holdings, 27,307 shares underlying options.

The Form 4 also reports an option grant with an exercise price of $18.09 and an expiration date of 06/21/2032. The filer notes the option grant was originally made on 06/21/2022 and that the underlying shares vest 100% one year from the grant date. The filing is signed by an attorney-in-fact on 10/02/2025.

Cecilia Jones, Chief Financial Officer of Agios Pharmaceuticals (AGIO) reported the vesting of 7,472 restricted stock units and a contemporaneous automatic sale of 3,651 shares to satisfy tax withholding obligations. The sale price reported was $36.77 per share, and following these transactions she beneficially owned 33,870 shares. The RSUs were originally granted on September 26, 2022 and vest in three equal annual installments beginning September 26, 2023. The tax-withholding sale was executed under pre-existing durable automatic sale instructions consistent with a Rule 10b5-1 plan.